
Advertise on podcast: Diabetes Connections | Type 1 Diabetes
Rating
4.7from
This podcast has
826 episodes
Language
EnglishPublisher
Stacey SimmsExplicit
No
Date created
2015/06/13
Latest episode
2026/11/17
Average duration
27 min.
Release period
6 days
Description
The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
Unlock Diabetes Connections | Type 1 Diabetes podcast Email contact info,
Listeners & Audience details
Email contact information
Direct podcast contact details

Listeners
Audience numbers & engagement insights

Audience details
Podcast Insights

Podcast episodes
Check latest episodes from Diabetes Connections | Type 1 Diabetes podcast
Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more!
2026/11/17
This week on Diabetes Connections In the News… two new tubeless pumps are cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns..
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Transcript:
This week on Diabetes Connections In the News… a new tubeless pump is cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns..
It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
We've got a lot to get to, so let's just dive in! Our top story this week:
XX
Big news – there are now FOUR tubeless insulin pumps FDA cleared. MiniMed Fit and tandem mobi tubeless cleared in the past week – add those to the Beta Bionics Mint and of course, the original, Omnipod.
Just yesterday, the FDA cleared the new MiniMed Fit system, which can be worn for up to seven days and holds 300 units of insulin. It has a reusable pump core and a Disposable cartridge – the cannula is built in, so no separate infusion set. Holds 300 units of insulin, with a built-in cannula and reliable adhesive for up to 7 day wear.
Reusable pump core — The brains of the pump, this rechargeable part attaches to the disposable cartridge. One charge lasts up to 7 days.The pump uses the same SmartGuard automated insulin delivery technology as MiniMed Flex, adjusting insulin and making corrections every five minutes.
The system is fully controlled by smartphone and will be available through pharmacies, with a phased U.S. rollout planned for 2027.
https://news.minimed.com/2026-11-16-FDA-Clears-MiniMed-Fit-TM-Worlds-First-and-Only-Tubeless-Insulin-Pump-with-Up-to-Seven-Day-Wear-and-Zero-Interruptions
XX
Just a few days ago, Tandem Diabetes Care received clearance clearance for a tubeless version of its Mobi insulin pump, with a wearable cartridge and infusion set designed to last up to seven days. Tandem plans a full U.S. launch in the first half of 2027, with distribution exclusively through pharmacies. This gives people with type 1 another potential option for automated insulin delivery without traditional pump tubing.
https://www.drugdeliverybusiness.com/tandems-mobi-pump-wins-fda-clearance-for-7-day-tubeless-wearable-set/
In other Tandem news, the company has issued a recall-related correction affecting more than 80,000 Mobi insulin pumps because of a problem that can trigger false occlusion alarms and interrupt insulin delivery. As of late October, Tandem had received reports of 230 adverse events requiring medical attention or hospitalization, although no deaths had been reported. The issue involves friction inside the pump's motor mechanism, which can cause the device to mistakenly detect a blockage. Tandem says customers can continue using their pumps but should respond promptly to alarms, keep a backup insulin delivery method available, and contact customer support if alarms repeatedly interrupt therapy. The company is investigating the problem and working to prevent it in future devices.
https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/
XX
Just in time for open enrollment, a new free tool aims to make choosing health insurance a little less overwhelming for people with diabetes. The GlucoSense Insurance Navigator compares 2027 Marketplace plans based on what you'll actually spend over the course of a year, not just your monthly premium. It factors in deductibles, insulin, CGMs, pump supplies, doctor visits, and even manufacturer savings cards to estimate your total annual costs. The tool's developers say early users have identified plans that could save them thousands of dollars a year. It's available through the GlucoSense app, although you'll still want to confirm coverage and costs directly with your insurance company before enrolling. Hat Tip to Justin from Diabetech as my source here..
https://www.diabetech.info/p/glucosense-launches-tool-to-help-people-with-diabetes-choose-insurance
XX
For the first time, the World Health Organization has issued guidelines specifically for diagnosing and managing type 1 diabetes in adults. Released on World Diabetes Day, the recommendations focus on making insulin, blood glucose monitoring, and quality care accessible worldwide, including in countries with limited healthcare resources. The WHO estimates that 9.5 million people worldwide were living with type 1 diabetes in 2025, with another half-million diagnosed that year. The guidelines recommend multiple daily insulin injections, regular glucose monitoring, and the use of CGMs when available. The larger goal is to ensure everyone with type 1 has access to affordable insulin and glucose monitoring by 2030.
https://www.who.int/news/item/14-11-2026-who-issues-first-guidelines-on-type-1-diabetes-for-adults
XX
XX
The FDA is requiring new safety warnings on all GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, because of a possible connection to a rare eye condition that can cause sudden vision loss. The condition, called NAION, occurs when blood flow to the optic nerve is reduced and can sometimes cause permanent damage. An analysis of clinical trials found about 6.4 cases per 100,000 patient-years among GLP-1 users, compared with 3.8 among those receiving other treatments or placebos. The FDA says the risk appears very small and researchers have not established that the medications directly cause the condition. Diabetes itself is also a risk factor, making the connection more difficult to untangle. We have an episode coming up next week where we'll talk a bit more about his.
https://www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html
A new study of more than 8,400 adults with type 1 diabetes in the Veterans Health Administration found that people who started using CGMs had a lower risk of death over the following four years. The estimated reduction in mortality risk was about 16 percent at four years, with potentially greater benefits for adults over 65 and those not using insulin pumps. Researchers emphasize that this was an observational study, so it doesn't prove CGMs directly caused the improvement. Still, the findings add another compelling argument for expanding access to diabetes technology.
https://www.emjreviews.com/en-us/amj/diabetes/abstract/continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-patients-with-type-1-diabetes-a-target-trial-emulation-study-using-national-healthcare-data-j04126/
XX
XX
Researchers are getting closer to understanding a long-standing mystery in type 1 diabetes: why children whose mothers have type 1 are about half as likely to develop the condition as children whose fathers have it. A University of Colorado study followed nearly 7,000 children at increased genetic risk and found that inherited genes don't explain the difference. The protective effect appears to happen early in life, particularly before age six, when the immune system may begin attacking insulin-producing cells. Researchers also found no evidence that pregnancy loss explains the difference, as some had previously suggested. The next step is figuring out what biological process might be providing that protection and whether it could eventually help prevent type 1 diabetes.
https://medicalxpress.com/news/2026-11-genetic-maternal-effect-diabetes.html
XX
Researchers in Israel are reporting promising early results from an experimental treatment for LADA, sometimes called type 1.5 diabetes. Scientists at Bar-Ilan University combined three drugs — GABA, sitagliptin, and omeprazole — and found that about 30 percent of treated mice returned to normal blood sugar levels without insulin, even after treatment ended. The researchers also identified blood markers that could predict which mice would respond, potentially opening the door to more personalized treatments. LADA is a form of autoimmune diabetes that typically develops more slowly in adults. This research is still in mice, not humans, but it offers an interesting new direction for treating autoimmune diabetes.
https://www.timesofisrael.com/israeli-scientists-use-common-drugs-to-cure-30-of-mice-with-type-1-5-diabetes/
XX
A fully automated artificial pancreas that delivers both insulin and glucagon is showing mixed results in a new year-long study involving more than 240 adults with type 1 diabetes. Unlike current hybrid closed-loop pumps, this system doesn't require users to count carbs, announce meals, or make adjustments for exercise. Researchers found it improved time in range by nearly two hours a day compared with multiple daily injections, but offered no
Finding Diabetes Joy: How Poetry Helped Ephraim Navigate a T1D Diagnosis
2026/11/13
In this bonus episode of Diabetes Connections, meet Ephraim Sommers, an English professor and poet diagnosed with LADA (a slower-developing form of type 1 diabetes) in his early 40s.
Even though his father has type 1, Ephraim wasn't prepared for the fear, anxiety, and mental load of managing diabetes himself.
So he turned to poetry. Every weekday, he sat in a coffee shop and wrote about gratitude. Those poems became Diabetic Gumdrops, a new book about finding joy while living with diabetes.
We talk about shifting from fear to gratitude, advocating for yourself, and why poetry might help even if you haven't read a poem since high school.
Plus, Ephraim lives right here in the Charlotte area! We had a great time talking about the local T1D community and how important connection can be.
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman
2026/11/10
This week on Diabetes Connections - looking into a very old vaccine to get new results for people with type 1. Dr. Denise Faustman's research into the BCG vaccine has been making headlines for a long time, and she's now sharing new results from her clinical trials, including some pretty remarkable claims about A1C, insulin use, and time in range.
Now, I know some of you may be surprised that I'm having Dr. Faustman on the show. She's a very controversial figure in the diabetes research world, and her work has sparked plenty of debate and skepticism over the years.
We're not ignoring any of that. In fact, we talk directly about the controversy, why she believes her research has faced resistance, and what it would take for BCG to become a widely accepted treatment.
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
More about Dr. Faustman's work here
More about the controversy and history here
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more
2026/11/03
This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for
sports on the highest level with type 1. And it's diabetes awareness momth!
It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy.
We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month.
Okay.. our top story this week:
XX
Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign.
https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs
XX
Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.
Statement from Dexcom:
We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information.
These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly.
Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time.
We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices.
XX
Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter.
Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned.
Source: Drug Delivery Business News
XX
In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications.
Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk.
Source: Medscape
XX
New research suggests that widely used tools for predicting heart disease risk may significantly underestimate that risk in people with type 1 diabetes. Researchers analyzed decades of data from more than 1,300 participants in the long-running DCCT/EDIC study and found that actual cardiovascular events occurred more frequently than several standard risk calculators predicted. Adding a coronary artery calcium scan, which looks for calcium buildup in the arteries, improved predictions somewhat, but not dramatically. The findings, presented at the 2026 European Association for the Study of Diabetes meeting, highlight the need for better heart disease risk assessment tools designed specifically for people with type 1.
Source: Medscape
XX
Eli Lilly is reporting impressive results for retatrutide, its experimental drug that targets three different hormone receptors, including GLP-1. In a Phase 3 study involving nearly 1,300 adults with type 2 diabetes, retatrutide lowered A1C by 2.2 percentage points, compared with 1.8 points for Ozempic. Participants taking retatrutide also lost an average of 44 to 47 pounds, roughly twice as much as those taking Ozempic. Side effects, including diarrhea and unusual skin sensations, were more common with retatrutide. The drug is not yet approved, and Lilly plans to seek FDA approval in early 2027.
Source: BioSpace
XX
It's official: MiniMed is now a fully independent company, completing its separation from longtime parent company Medtronic. MiniMed went public earlier this year, and Medtronic has now exchanged its remaining shares, ending its ownership stake in the diabetes technology business. MiniMed CEO Que Dallara says the independence gives the company more freedom to make decisions and advance diabetes care. The company is still working to separate some of its technology services from Medtronic, a process expected to continue into 2027.
Source: MedTech Dive
XX
Still to come, an implant designed to remove excess glucose without medication, help for younger adults with type 2, and type 1 hits the streets of new York.. right after this.
XX
Scientists in Switzerland and France have developed an experimental implant that removes excess glucose from the blood without using insulin or other diabetes medications. The tiny wireless device works with a continuous glucose monitor and uses an electrical reaction to convert glucose into a substance called gluconate, which is then cleared by the kidneys. In mice with type 2 diabetes and obesity, the device lowered blood sugar and reduced body weight by about 10% over six weeks. Researchers say the technology could eventually offer a new approach to treating type 2 diabetes, but it's still in the very early stages, with no human trials yet.
Source: Live Science
XX
A new study suggests that an intensive diet and exercise program can help some younger adults with type 2 diabetes achieve remission in just six months. Researchers followed 96 adults under age 45 and found that 54% of those in a medically supervised program achieved remission, compared with just 4% receiving standard care. The program included a very low-calorie diet of 800 to 900 calories per day during its initial phase, along with structured aerobic and strength training. Remission means blood sugar returns below the diabetes threshold without glucose-lowering medication, but it doesn't necessarily mean a permanent cure. These findings apply to type 2 diabetes, not type 1, and the intensive program was conducted under medical supervision.
Source: ScienceDaily
XX
Two big shoutouts for type 1 diabetes and sports. Major congrats to everyone who completed or even attempted the NYC Marathon – I'm in awe of how much training you've all put in. What an amazing accomplishment. And of course, I know some time has gone by, but one more mention of Garrett Mitchell from the World Series champion Milwakee Brewers.
A big week for people with type 1 diabetes in sports! Congratulations to everyone with T1D who took on the New York City Marathon, and a special shoutout to Milwaukee Brewers outfielder Garrett Mitchell. We'll have more on Mitchell and his story coming up.
XX
I anticipate a lot of diabetes month news and campaigns and I'll share on social if I find them interesting and actionable. I don't really do much that's different – every month is diabetes awareness month around here. I do think it's a wonderful time to get information out to the non-diabetes community. Project Blue Novmeber always does a great job all month long if you're looking to shrae iformatoin via social.
That's it for in the news!
This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely
What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill
2026/10/27
What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes.
I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care.
We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it.
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
More about the Congress here
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Meet GLUKI, the T1D App Helping Kids Learn Through Play
2026/10/23
On this bonus episode of diabetes connections.. the creator of Gluki, a new app designed to help kids understand diabetes through games, rewards, and interactive learning.
I'm talking to Staci DePatie who lives with type 1. Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it's as part of a game.
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
In the News.. Dexcom controversy, New T1D research, and a World Series moment to remember!
2026/10/20
This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series!
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Transcript:
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up.
Off to Seattle in a couple of days for MNO..
Okay.. our top story this week:
XX
Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.
The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms.
The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features.
Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here..
(clip)
I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration.
I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update.
XX
Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.
XX
SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective.
https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html
XX
Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes.
https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe
XX
A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1
diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10
XX
A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy.
T1d pregnancy and me study team, we did an episode on this.
XX
A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary.
https://www.sciencedaily.com/releases/2026/10/261017230031.htm
XX
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).
From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.
"Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shapi
Sernova + Seraxis: A New Partnership in the Race for a T1D Cure with CEOs Johnathan Rigby and Dr. Will Rust
2026/10/13
A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.
So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?
I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 - and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.
Our past episodes with Sernova here
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
What's Next for Dexcom? G8, New Research & Your Questions with Jessica Castle, VP Global Medical Affairs
2026/10/11
On this bonus episode of Diabetes Connections, catching up with Dexcom after the EASD international conference. I'm asking your questions about longer sensor wear for kids, changes to adhesive, what's going on with the G8 and more.
Plus Dexcom presented a few studies at the summer conferences about some pretty significant benefits of CGM, including fewer DKA-related hospital visits for people with type 1 and improved glucose outcomes for people with type 2 who aren't using insulin.
This podcast is not meant at medical advice, if you have those types of questions, please ask your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
In the News... Experimental new peptide for T2D, low-carb studies in kids, GLP-1 pill info, gaps in CGM access, fashion line honors a T1D icon, and more!
2026/10/06
This week on Diabetes Connections In the News…
A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.
Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.
And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
This week on Diabetes Connections In the News…
A new combination drug shows big weight loss and A1C improvements for people with type 2. New guidance aims to cut down on adults being misdiagnosed with the wrong type of diabetes. Could trying to keep your glucose too steady affect your quality of life? Very low-carb diets for kids with type 1, and new research on putting early-onset type 2 into remission. The FDA clears an app that recommends insulin dose changes directly to people using injections—and approves a once-a-week insulin for type 2.
Plus, new data on Lilly's daily GLP-1 pill, gaps in CGM access for type 2, and a surprising study looking at type 1 and the rotavirus vaccine.
And what do sex and running a marathon have in common? Two new studies look at type 1 diabetes, physical activity, and the risk of low blood sugar.
All that and more, coming up! It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Super excited to tell you that we have joined the Health Podcast Library! Over the years, I've been asked to join a lot of networks – and I've thought about starting my own – but this is the first one that made sense to me. Health Podcast Library is a free place to find health podcasts from credible people and organizations. The creators and organizations producing each show are reviewed before it is listed. They believe sourcing matters. They don't pay me to be there and I'm proud to say I'm the first Diabetes Show featured on the Library to sign their The Health Content Integrity Pledge is a commitment from creators across all health topics and platforms to continuously work toward embedding evidence-based principles in their content creation and platform management. As creators of health-related content, we recognize our responsibility to provide accurate, transparent, and credible information that helps people make informed decisions about their health and well-being.
Go check it out and if you're a health podcaster, consider joining.
https://healthpodcastlibrary.com/
Health podcast networks
Okay.. our top story this week:
XX
Eli Lilly says an experimental drug combination helped people with obesity or overweight and type 2 diabetes lose an average of 23.3% of their body weight over 48 weeks, while also improving A1C. The treatment, called eloraTZP, combines the experimental drug eloralintide with Lilly's approved diabetes and weight-loss medication Zepbound. At the highest dose, participants lost an average of 54.1 pounds. The results are notable because people with type 2 diabetes typically lose less weight with obesity medications than people without diabetes.
The study included 367 adults with type 2 diabetes and obesity or overweight. The combination targets three hormones involved in blood sugar, digestion and appetite: GIP, GLP-1 and amylin. Side effects, mainly gastrointestinal, were more common with the combination, and as many as 27% of participants taking eloraTZP stopped treatment. Lilly plans to begin phase 3 trials later this year.
https://www.fiercebiotech.com/biotech/lilly-raises-weight-loss-bar-its-amylin-zepbound-combo
XX
New research suggests that for people with type 1 or type 2 diabetes, keeping glucose as steady as possible may not always translate into a better quality of life. In a study of 400 people with diabetes, researchers found that spending more time in the normal glucose range was associated with better quality of life the following day. Surprisingly, greater glucose variability was also linked to better next-day well-being, as long as glucose remained within safe limits.
The findings, presented at the European Association for the Study of Diabetes annual meeting in Milan, do not suggest that high or low blood sugar is beneficial. Instead, researchers say they may point to a tradeoff in diabetes management: the effort and restrictions involved in trying to eliminate every glucose fluctuation could sometimes interfere with everyday activities and enjoyment of life. The study combined continuous glucose monitor data with daily assessments of mood, energy, sleep, stress and overall well-being.
https://www.sciencedaily.com/releases/2026/09/260927225019.htm
XX
New guidance from the American Diabetes Association and European Association for the Study of Diabetes puts a major focus on correctly diagnosing type 1 diabetes in adults. The report says about 40% of people diagnosed with type 1 after age 30 are initially misdiagnosed as having type 2 diabetes. It emphasizes that type 1 can develop at any age and that adults with the condition may have overweight or obesity, so age and body size alone shouldn't be used to determine diabetes type.
The updated guidance recommends islet autoantibody testing when type 1 diabetes is suspected and, in some cases, C-peptide testing to determine how much insulin the body is still producing. It also discourages use of the term "LADA," or latent autoimmune diabetes in adults, saying these cases are better classified as type 1 diabetes. The report also includes expanded guidance on diabetes complications, cardiovascular risk, obesity, exercise, nutrition and mental and emotional health.
https://www.medscape.com/viewarticle/guidance-type-1-diabetes-management-adults-updated-2026a1001080
XX
Eli Lilly says its once-daily GLP-1 pill Foundayo, also known as orforglipron, lowered A1C and weight while demonstrating cardiovascular safety in adults with type 2 diabetes and obesity or overweight who were at increased risk for heart problems. In the study, participants taking Foundayo lowered their A1C by 1.6 percentage points and lost an average of 8.8% of their body weight, or nearly 18 pounds, after one year. Those taking long-acting insulin lowered A1C by 1 percentage point and gained an average of 1.7% of their body weight.
Foundayo was also found to be at least as safe as insulin glargine when researchers looked at major cardiovascular events, including heart attack and stroke. The study also reported improvements in blood pressure, waist circumference and cholesterol, along with a slower decline in kidney function. The results were presented at the European Association for the Study of Diabetes annual meeting in Milan and published in The Lancet.
https://www.fiercepharma.com/pharma/lilly-gives-deeper-glimpse-foundayos-heart-helping-odds-diabetes-obesity-phase-3
XX
A large Norwegian study found that type 1 diabetes diagnoses among young children increased after the country introduced routine rotavirus vaccination in 2014. Researchers followed more than 740,000 children and found that the rate of type 1 diabetes before age 5 was 11% higher than expected based on trends before the vaccine was introduced. The findings were presented at the European Association for the Study of Diabetes annual meeting and published in Diabetologia.
Importantly, the study does not show that the rotavirus vaccine causes type 1 diabetes. When researchers compared fully vaccinated children directly with unvaccinated children, the difference in type 1 diabetes risk was not statistically significant. Researchers had been studying the vaccine because infections, including rotavirus, have been investigated as possible environmental factors affecting type 1 diabetes risk, and previous studies have produced conflicting results.
https://www.news-medical.net/news/20261001/Type-1-diabetes-incidence-rose-by-1125-after-rotavirus-vaccine-rollout-in-Norway.aspx
XX
A large study of children with type 1 diabetes found that very low- and low-carbohydrate diets were associated with better blood sugar control and lower insulin needs, without evidence of impaired growth or increased rates of severe low blood sugar or diabetic ketoacidosis. The research included more than 45,000 children ages 1 to 17 and used up to 25 years of data. The findings were presented at the European Association for the Study of Diabetes annual meeting in Milan.
Children eating fewer carbohydrates also had smaller increases in BMI and A1C over time compared with those eating standard or higher
Moving Diabetes Solutions Forward: Beyond Type 1's Innovation Accelerator
2026/10/04
On this bonus episode of diabetes connections, we're talking about the Beyond Barriers Innovation Accelerator. This is a project from Beyond Type 1 which is investing in community-based organizations and entrepreneurs working to close those gaps. We'll hear about some really interesting projects from comic books for kids to apps for first responders and programs to help with cost…
And we'll zoom out: eleven years after Beyond Type 1 launched, what is the organization today—and how is it trying to make sure more people with diabetes have the opportunity not just to survive, but to thrive? What's the mission for Beyond Type 1 in 2026?
This podcast is not intended as medical advice, if you have those kinds of questions, please contact your healthcare provider.
More about the Innovation Accelerator and Beyond Type 1 here
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Sharing T1D With the World: Shannon Boggs on Parenting, Independence & Community
2026/09/22
Shannon Boggs' daughter Raelynn, was still doing backflips at gymnastics just days before she landed in the ICU in DKA and was diagnosed with type 1 diabetes.
Four years later, things look very different. Raelynn is starting middle school, taking on more of her own diabetes management, going to regular sleepaway camp, and even sharing her life with type 1 online — with hundreds of thousands of people following along.
Shannon and I talk about that sometimes-scary balance between independence and diabetes management, why finding community changed everything for their family, and how she thinks about sharing Raylan's diabetes, and her whole family's story, so publicly on social media.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Check out all of our events like Moms' Night Out and Club 1921 here.
Info about the bananas Chesapeake Bay Bridge Tunnel here
Announcing Community Commercials! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
In the News.. ADA Boycott, new patch pumps, endometriosis and type 2 risk, Zverev wins US Open with T1D, and more!
2026/09/15
On this episode of Diabetes Connections In the news…
The ADA conference controversy continues with a boycott now, new patch pump approved, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Join us for a webinar September 23
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Transcript:
On this episode of Diabetes Connections In the news…
The ADA conference controversy continues with a boycott now, an update on long running research to reverse type 1, plus consensus guidelines on T1D screening, intermittent fasting for type 1, a new surprising study about COVID and T1D, statins, type 2 and dementia, and lots more..
It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
We are off to Detroit this week for Moms' Night Out in Bloomfield Michigan. Super excited and as usual I'm getting last minute emails and DMs about respiration from people just finding out about the event. We will always figure it out so drop me a line. But please register now for Seattle next month! Tampa will be open soon as well!
Want to let you know about a webinar I'm doing with Abbott later this month. That's Sept 23 at 7pm ET. We'll be talking about ketones, DKA and learn more about their dual CGM/ketone monitor that was just approved. Great crowd already registered for that, hope you can join us. The link is in the show notes.
Okay.. our top story this week:
XX
Member of the American Diabetes Association… are now boycotting it. The notice of the boycott condemns leadership's actions after five researchers were removed by police from its annual meeting in June.
Significantly, The editors of ADA's flagship journal, Diabetes Care, have joined on in support of the boycott.
"Manuscripts submitted will not be handled until the boycott is over," said Steven Kahn, MBChB, the journal's editor in chief and one of the five researchers ejected from the meeting in New Orleans, in a LinkedIn post on Thursday.
Kahn told MedPage Today that "the journal boycott is like establishing a picket line.
The boycott already has hundreds of signatures of people who have pledged to suspend all ADA-related activities, including:
Planning or attending any meetings led by ADA leadership or the board, including the 2027 ADA Scientific Sessions
Participating in board-led activities regarding the investigation of the meeting's events, or the report generated by the "so-called 'independent' committee"
Engaging in all other ADA operations, including presentations, fundraisers, grant reviews, manuscript reviews, journal management, manuscript submissions, and position statements
The boycott will remain active until the ADA board of directors permits an independent formal review of the organization's structure and function to ensure it "properly represent[s] its professional membership." If demands are not met, signees plan to align with existing or newly formed medical societies.
https://www.medpagetoday.com/endocrinology/diabetes/122977
https://docs.google.com/forms/d/e/1FAIpQLSd4h548X9qXgkVREQ71k2gDHiU8WFAFF78wTnmS20_ntwUM0w/viewform
XX
A new patch pump is coming to the US.. Beta Bionics, Inc. announces FDA clearance of Mint, the Company's patch pump featuring a transformative reusable and disposable architecture that does not require recharging, integrates with industry-leading continuous glucose monitors (CGM) and enables smartphone control for iOS and Android users.
The Company expects to initiate the full commercial launch of Mint in the United States in the first quarter of 2027
Mint is expected to launch exclusively through the pharmacy channel.
Also announced, that Eversense 365 is now compatible with Beta Bionics Senseonics expects development of the Eversense 365-iLet integration to be
completed during the fourth quarter of 2026. Commercial launch is planned following completion of integration activities in the fourth quarter of 2026, subject to required testing, validation activities and applicable regulatory requirements. No word yet on timing for Eversense with Mint.
https://www.manilatimes.net/2026/09/14/tmt-newswire/globenewswire/beta-bionics-announces-fda-clearance-of-mint-the-companys-transformative-patch-pump-and-unveils-3d-intelligence-as-its-next-generation-insulin-dosing-algorithm/2424457
XX
Seven years after Johns Hopkins researchers discovered a previously unknown immune cell called the "X cell," they're now exploring whether that discovery could lead to a new treatment for type 1 diabetes.
In preclinical studies, researchers developed an antibody that was able to target and eliminate specific immune cells responsible for attacking the pancreas's insulin-producing beta cells, while leaving the rest of the immune system intact.
The researchers say the approach is especially promising because it could potentially reverse the autoimmune process soon after a type 1 diabetes diagnosis, rather than simply managing blood sugar. The work is still in the early stages and has not yet been tested in people; additional laboratory and preclinical studies are needed before human clinical trials can begin.
sclerosis.https://hub.jhu.edu/2026/09/09/federal-funds-support-type-1-diabetes-treatment/
XX
A new international consensus recommends routine screening for type 1 diabetes in the general population, offering the first framework for how healthcare providers could put widespread screening into practice. The guidance recommends screening children between ages 2 and 4, with children who test negative screened again at ages 6–8 and 10–15. Screening uses a blood test to look for islet autoantibodies, which can signal that the immune system is attacking insulin-producing cells years before symptoms appear or insulin is needed. Finding type 1 diabetes early can greatly reduce the risk of diabetic ketoacidosis, or DKA, at diagnosis and may give people access to treatments such as teplizumab that can delay progression to clinical T1D.
https://www.prnewswire.com/news-releases/breakthrough-t1d-convened-paper-outlines-first-international-consensus-guidance-on-general-population-screening-for-early-stage-type-1-diabetes-302875788.html
XX
Eating only between noon and 8 p.m. improved blood sugar control in a small study of adults with Type 1 diabetes and obesity, while avoiding an increase in serious complications. The promising findings offer the first evidence that time restricted eating could become another tool for managing the condition.
For the study, Varady recruited adults with Type 1 diabetes who were also classified as obese
After six months, the time-restricted eating group showed better blood sugar results than the calorie-reduction group. HbA1c, a blood test that reflects average blood sugar over the previous several months, fell by about 0.5% on average in the time-restricted group.
Couple of things here – very small study, only 32 people in total, who were then randomly placed in three groups with different styles of eating. Also, the lead researcher says this is the first study of it's kind for type 1 – which is obviously not true – you can do a quick google search or listen to past episodes of this show..
https://www.sciencedaily.com/releases/2026/09/260909231740.htm
XX
A large Danish study found that COVID-19 infection was associated with a slightly lower, rather than higher, risk of subsequently developing type 1 diabetes in people under age 30. Researchers studied more than 2,100 people diagnosed with T1D and found an overall 16% lower risk following a documented COVID infection, with the strongest association—a 42% reduction—seen 31 to 180 days after infection. The reduced risk appeared primarily among people who had not been vaccinated against COVID-19, although researchers cautioned that the vaccination findings were less certain. Importantly, this was an observational study, so it cannot show that COVID infection actually protects against type 1 diabetes or explain what caused the association. Researchers say the findings conflict with some earlier studies and should be investigated in other countries and populations.
https://www.news-medical.net/news/20260908/COVID-19-linked-to-lower-subsequent-risk-of-type-1-diabetes.aspx
XX
Semaglutide, a medication widely used for type 2 diabetes and weight loss, may also provide an unexpected benefit for people with asthma. New research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain, found that semaglutide use
Eversense 365 + twiist: New Data & What's Next for the Implantable CGM
2026/09/08
This week on Diabetes Connections.. Now that Eversense 365-day has been out in the real world and is working with the twiist automated insulin delivery system, we're starting to get a much better picture of what that combination can actually do.
This week, Dr. Fran Kaufman is back with new data on Eversense 365, including some impressive results from people using it with twiist. We'll talk about what they're learning, who's using the year-long sensor, and what may be coming next.
And that next step is really interesting: a sensor with its own battery that could work even when the external transmitter is removed, and eventually, a fully implanted CGM that could send glucose data directly from under your skin to your phone or watch.
Plus, we talk about pediatric plans, additional pump integrations, and why — after 50 years in diabetes care — Fran says she's more excited about the future than ever.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Join us for a Webinar with Abbott: Expert Discussion: Navigating Continuous Ketone Monitoring and DKA With Confidence - Register Here
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Type 1 Diabetes Screening Has Changed. What You Need to Know Now (Bonus episode)
2026/09/06
A few years ago, when we talked about screening for type 1 diabetes, it still felt a little bit like we were talking about the future. That future may be arriving faster than we realize.
Dr. Bryce Nelson is back on the show. After years as a pediatric endocrinologist, he's now working specifically in autoimmune type 1 diabetes with Sanofi. We talk about how much has changed with screening, what we're learning about who's at risk, and the big question: how close are we to screening becoming a routine part of healthcare?
And Jenny Hoffman shares what this looks like for a family living it. Her older son was diagnosed at two and a half; after years of screening her younger son, Asher, he tested positive for five autoantibodies at age six. He's still in stage one, and Jenny talks about the surprising difference between fearing a diagnosis and having the time to prepare for one.
Where is type 1 screening headed next? That's what we're talking about today.
This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider.
Learn more about screening: https://www.screenfortype1.com/
Check out all of our events like Moms' Night Out and Club 1921 here.
Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom
All about VIVI Cap to protect your insulin from extreme temperatures
The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here
Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!
Learn more about everything at our home page www.diabetes-connections.com
Podcast reviews
Read Diabetes Connections | Type 1 Diabetes podcast reviews
Type 1 In Midlife 2026/07/28
A Must-Listen for Anyone Touched by Type 1 Diabetes
Longtime listener of the show and honored to be a guest and bring my passion and story to the listeners. Stacey brings a welcoming space to share all ...
kd949 2026/04/03
Kelly Dawes Grownup T1Ds
Really appreciate the wide range of topics and perspectives shared on this podcast. Stacey is a fantastic host and the show covers a wide range of top...
Myopinionnow1 2025/06/14
Great resource and interviews
Stacey is a great interviewer and really cares about our community.
Alisonskis 2025/04/25
Great interviewer!
Stacey asks the BEST questions that, as a person with T1D, I would ask!
Victortilla t1d🦋🦋 2024/11/28
host is annoying
the info is okay, but the host is not. i find scott benner’s juicebox podcast mush easier and more fun to listen to.
22Michelle22 2024/11/13
Innovative and Insightful Diabetes Discussions!
Love hearing all the innovation and insights with Stacey and her guests! Stacey makes complex diabetes topics feel personal and easy to understand. He...
Me rpm 2024/08/27
So good!
Stacey is so good at this! I learn a ton from the newsmaker interviews and get inspiration from the personal ones
Mendelmy 2024/04/09
Amazing!
Stacey has such a casual yet knowledgeable demeanor and a great podcast voice too! Highly recommend!
Ksparl 2024/04/01
Stacey Really Gets It
As a longtime PWD, I really value the perspectives shared by the parents of kids with diabetes. Stacey’s insights, humility, and honesty as a parent a...
UNCTroutman 2024/01/18
A no-fluff, GREAT listen!
Stacy finds great guests with expertise / experience that add value. A no-fluff but great listen!
Podcast sponsorship advertising
Start advertising on Diabetes Connections | Type 1 Diabetes relevant audience podcasts
You may also like to advertise on these Podcasts

4.116097472
The Tucker Carlson Show
Tucker Carlson Network

4.828116459
Huberman Lab
Scicomm Media

4.240683
To Be The Man
Podcast Heat | Cumulus Podcast Network

4.41511762000
The Ben Shapiro Show
The Daily Wire

4.2155648
TENNIS.com Podcast
TENNIS.com Podcast/Tennis Channel Podcast Network

4.510882780
The Joe Budden Podcast
The Joe Budden Network

4.611699506
The Bulwark Podcast
The Bulwark

4.711532393
Matt and Shane's Secret Podcast
Matt McCusker & Shane Gillis

4.72580183
Smosh Reads Reddit Stories
Smosh

4.975278756
Small Town Murder
James Pietragallo, Jimmie Whisman